Grant: Engage Grants Program
McMaster University
$25,000.00
New cardiovascular simulator for coarctation of the aorta and coarctation-related devices
EF 2017-18
Résumé
COMPANY BACKGROUND: ViVitro Labs Inc. is a Canadian-based company that has providedcardiovascular and endovascular device test equipment and laboratory testing to a global market. It is the onlyCanadian company making cardiovascular and endovascular device test simulators. The ViVitro PulseDuplicator system is the world's most cited and used in vitro hemodynamic testing system for commercial heartand valve devices. THE NEED: Although the ViVitro simulators have the capability of testing somecardiovascular diseases and cardiovascular devices, they do not have the capability of testing the mostimportant and common congenital cardiovascular pathology: coarctation of the aorta (COA). COA is anarrowing of the aorta with many morphologic variants. A physical COA simulator is much needed fordesigning, developing, evaluating and optimizing COA-related devices, especially the emerging vasculartranscatheter stents, and for developing novel diagnostic methods for COA. COLLABORATIONOPPORTUNITY: This collaboration allows ViVitro to investigate feasibility of adding the capability of testingof COA and COA-related devices to its product portfolio using an innovative approach. METHODOLOGY:This project uses clinical imaging data, image processing algorithms, and a unique computational fluiddynamics and lumped parameter modeling framework to provide details of the physiological pulsatile flow andpressures through the heart and the circulatory system. This information is required for developing andvalidating the setup to simulate the physiological condition. OPPORTUNITY: The new simulator can servetesting needs of medical-device companies that want to introduce new devices for COA. This simulator is alsovery attractive for academic research worldwide. This is particularly important because the industrial focus onvascular transcatheter stents and related devices is rapidly growing and the number of companies developingnew vascular devices is greatly increasing. The new simulator can help ViVitro Labs to differentiate in theinternational market of endovascular device simulators and can create new jobs in Canada.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
516329-2017
Name nom
KeshavarzMotamed, Zahra
Department département
Mechanical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1903
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomechanics
Research subject fr
Biomécanique
Partie
1
Nb partie
1
Application title
New cardiovascular simulator for coarctation of the aorta and coarctation-related devices
Keyword
NSERC
Application summary
COMPANY BACKGROUND: ViVitro Labs Inc. is a Canadian-based company that has providedcardiovascular and endovascular device test equipment and laboratory testing to a global market. It is the onlyCanadian company making cardiovascular and endovascular device test simulators. The ViVitro PulseDuplicator system is the world's most cited and used in vitro hemodynamic testing system for commercial heartand valve devices. THE NEED: Although the ViVitro simulators have the capability of testing somecardiovascular diseases and cardiovascular devices, they do not have the capability of testing the mostimportant and common congenital cardiovascular pathology: coarctation of the aorta (COA). COA is anarrowing of the aorta with many morphologic variants. A physical COA simulator is much needed fordesigning, developing, evaluating and optimizing COA-related devices, especially the emerging vasculartranscatheter stents, and for developing novel diagnostic methods for COA. COLLABORATIONOPPORTUNITY: This collaboration allows ViVitro to investigate feasibility of adding the capability of testingof COA and COA-related devices to its product portfolio using an innovative approach. METHODOLOGY:This project uses clinical imaging data, image processing algorithms, and a unique computational fluiddynamics and lumped parameter modeling framework to provide details of the physiological pulsatile flow andpressures through the heart and the circulatory system. This information is required for developing andvalidating the setup to simulate the physiological condition. OPPORTUNITY: The new simulator can servetesting needs of medical-device companies that want to introduce new devices for COA. This simulator is alsovery attractive for academic research worldwide. This is particularly important because the industrial focus onvascular transcatheter stents and related devices is rapidly growing and the number of companies developingnew vascular devices is greatly increasing. The new simulator can help ViVitro Labs to differentiate in theinternational market of endovascular device simulators and can create new jobs in Canada.